[go: up one dir, main page]

MXPA03001609A - Derivados de cromenona. - Google Patents

Derivados de cromenona.

Info

Publication number
MXPA03001609A
MXPA03001609A MXPA03001609A MXPA03001609A MXPA03001609A MX PA03001609 A MXPA03001609 A MX PA03001609A MX PA03001609 A MXPA03001609 A MX PA03001609A MX PA03001609 A MXPA03001609 A MX PA03001609A MX PA03001609 A MXPA03001609 A MX PA03001609A
Authority
MX
Mexico
Prior art keywords
receptors
hta1
dopamine
conjunction
treating diseases
Prior art date
Application number
MXPA03001609A
Other languages
English (en)
Inventor
Christoph Seyfried
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA03001609A publication Critical patent/MXPA03001609A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03001609A 2000-08-24 2001-07-24 Derivados de cromenona. MXPA03001609A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041574A DE10041574A1 (de) 2000-08-24 2000-08-24 Chromenonderivate
PCT/EP2001/008528 WO2002016354A1 (de) 2000-08-24 2001-07-24 Chromenonderivate und ihre verwendung zur behandlung von krankheiten im zusammenhang mit 5-hta1-rezeptoren und/oder dopamin-d2-rezeptoren

Publications (1)

Publication Number Publication Date
MXPA03001609A true MXPA03001609A (es) 2003-06-04

Family

ID=7653636

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001609A MXPA03001609A (es) 2000-08-24 2001-07-24 Derivados de cromenona.

Country Status (16)

Country Link
US (1) US20040014768A1 (es)
EP (1) EP1311503A1 (es)
JP (1) JP2004506733A (es)
KR (1) KR20030022390A (es)
CN (1) CN1447807A (es)
AU (1) AU2001289735A1 (es)
BR (1) BR0113364A (es)
CA (1) CA2420206A1 (es)
CZ (1) CZ2003659A3 (es)
DE (1) DE10041574A1 (es)
MX (1) MXPA03001609A (es)
NO (1) NO20030811D0 (es)
PL (1) PL359222A1 (es)
SK (1) SK2942003A3 (es)
WO (1) WO2002016354A1 (es)
ZA (1) ZA200302255B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005091722A2 (en) 2004-03-26 2005-10-06 Lg Electronics Inc. Recording medium and method and apparatus for reproducing text subtitle stream recorded on the recording medium
WO2005091728A2 (en) * 2004-03-26 2005-10-06 Lg Electronics Inc. Recording medium, method, and apparatus for reproducing text subtitle streams
KR20130132932A (ko) * 2010-12-20 2013-12-05 아스트라제네카 아베 2-카르복스아미드-4-피페라지닐-벤조푸란 유도체
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN116332918B (zh) * 2023-03-17 2025-07-25 遵义医科大学珠海校区 香豆素-喹啉衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
DE4111861A1 (de) * 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung

Also Published As

Publication number Publication date
JP2004506733A (ja) 2004-03-04
US20040014768A1 (en) 2004-01-22
DE10041574A1 (de) 2002-03-07
KR20030022390A (ko) 2003-03-15
BR0113364A (pt) 2003-07-15
PL359222A1 (en) 2004-08-23
EP1311503A1 (de) 2003-05-21
CN1447807A (zh) 2003-10-08
SK2942003A3 (en) 2003-09-11
NO20030811L (no) 2003-02-21
NO20030811D0 (no) 2003-02-21
ZA200302255B (en) 2004-08-16
CA2420206A1 (en) 2003-02-21
CZ2003659A3 (cs) 2003-06-18
AU2001289735A1 (en) 2002-03-04
WO2002016354A1 (de) 2002-02-28

Similar Documents

Publication Publication Date Title
MXPA03005923A (es) Derivados de glupopiranosiloxipirazol y su uso en medicinas.
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
MXPA03002275A (es) Aplicadores de inserto para incontinencia.
HUP0300746A3 (en) Proline derivatives and use thereof as drugs
MXPA03004644A (es) Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
ZA200207489B (en) Apomorphine derivatives and methods for their use.
PL377791A1 (pl) Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
HUP0303568A3 (en) Benzothiophene derivatives, process for their preparation and use thereof
IL155520A0 (en) Benzoxazinone derivatives, their preparation and use
HRP20041157A2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
MXPA03001609A (es) Derivados de cromenona.
HUP0302065A3 (en) Chromanone derivatives, production and use thereof
HUP0600238A3 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
HUP0301040A3 (en) Paraziticidal 13-substituted milbemycin derivatives, composition and use thereof
IL155853A0 (en) Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
IL156160A0 (en) Klainetins and their derivatives, method for their preparation and use thereof
PL340775A1 (en) Pharmacological agent for local application in treating parodontium diseases
IL151216A0 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
GB0026428D0 (en) Hydroimidazolone derivatives and their use in therapy
SI1309594T1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof